NEW YORK, August 6 /PRNewswire-FirstCall/ -- Biocoral, Inc. (OTCBB-BCRA) announced today that recently the French Patent Office (Institut National de la Propriete Industrielle "INPI") approved and granted a company patent called "Process of Purification of Coral and its use".
The French Patent Office, after more then three years of examining of the company's application, granted the patent innovation to Bio Holdings International Ltd., the Company's wholly owned subsidiary, under the patent number 03 14299. The Patent will expire in 2023.
The INPI is a French Government Agency Patent Office, which contributes to the development of industry by securing and protecting the successful and creative development of structures for patents, etc. The INPI represents France in the qualified international organizations and to cooperate to support the exchanges.
Biocoral(R) Company's primary product is a natural coral "Carbonate Calcium" derived bone graft substitute and is used by surgeons and practitioners because of its biocompatibility, resorbability, osseo conduction and safety. The original patent protecting the use of coral as bone substitute was filed in 1979 with its international extension in many countries around the world by French government agency in charge of scientific research (Centre National de la Recherche Scientifique "CNRS") before being taking over by the company subsidiary in the mid 1980's.
For the past six years, the Company has collaborated with accredited scientists as well as with a special laboratory located at one of most prestigious European universities to develop a method of purification of its raw material "coral," in order to remove the trace amounts (between 0.016 to 0.026% depending upon the type of coral used) of amino acids which were present, without any change in chemical and crystalline structure of the coral. As a result of these efforts, the small percentage of amino acid can now be removed from the Company raw material.
Nasser Nassiri, the Chairman and Chief Executive Officer of Biocoral, Inc. commented, "The purification of our raw materials permits us to improve their performance and to offer what we believe to be the only natural solely mineral bone substitute product in the world."
Nasser Nassiri, further commented that, "The Company have filed a patent with an international extension for the method of purification of its raw material and the final product issued using the method. The granting of this patent insures protection of the company's primary product "Biocoral(R)" until 2023. The Company believes that in the near future the company's patents covering this technology will receive approval in many other countries where the company has already filed its applications."
About Biocoral, Inc.
Biocoral, Inc., a Delaware corporation, is an international biomaterials "tissue-engineering" company specializing in the research and development of proprietary health care patented high technologies and biomaterials.
Biocoral(R), the Company's primary product, is a natural coral "carbonate Calcium" derived bone graft substitute and is used by surgeons and practitioners because of its biocompatibility, resorbability, osseo conduction and safety. Certain chemical, physical and structural characteristics of coral are very similar to that of human bone tissue. Biocoral(R) is derived from three particular species of coral naturally present in abundance. Biocoral(R) is primarily (more than 98%) comprised of calcium carbonate. Porous and resorbable, Biocoral(R) is prepared in microgranules as well as in engineered shapes according to specific indication. Due to its similarity to bone tissue, Biocoral(R) is compatible, resorbed by the body as new bone growth invades the Biocoral(R) and is replaced by neoformed invasion. It is highly porous with numerous interconnected channels which allow a total migration to the center of the implant free of contamination risk. Because Biocoral(R) is resorbed, it can be combined with antimicrobials, anticancer agents or other pharmaceuticals for slow release into bone tissue, resulting in an advantage over autologous bone grafts. The principal current alternative to Biocoral(R) is the utilization of autologous (from the patient's own body) bone grafts. The use of autologous bone grafts requires the patient to undergo one or more additional surgeries to harvest the bone graft material. This is not always feasible due to the condition of the patient or other contraindications, and must be shaped in a separate procedure to fit the graft area.
Through its subsidiaries, the Company researches, develops, manufactures and commercializes bone graft substitutes and other high tech patented biomaterials in a number of countries outside the United States. Biocoral, Inc. through its subsidiaries has developed the additional twelve titles of patents for various applications and uses of its products, such as a method of treating a disease associated with demineralization or mineralization bone defects ("osteoporosis remediation"), and combination with growth factor, among others. With these patents titles applications in various countries in the European Community, Canada, the United States, Japan, Australia, and Switzerland, the Company owns more than 219 patent applications around the world, and approximately 166 of these have thus far been granted by various countries' official government patent offices, including most European Community countries, Canada, Australia, Japan and in the United States by the US Department of Commerce Patent and Trademark Office.
The information contained in this press release, including any "forward looking" statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 contained herein, should be reviewed in conjunction with the Company's Annual Report on Form 10-KSB and other publicly available information regarding the Company, copies of which are available from the Company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business and such statements, including risks and uncertainties related thereto that are unpredictable and outside of the influence and/or control of the Company.